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The ongoing JANUS project was started in 1973. The serum bank comprises 424,938 serum samples consolidated from 293,692 donors. The speci-
mens are stored at -25°C. From 1 to 13 consecutive samples are available from each donor. Up to October 1993 about 14,000 of the donors had
developed some form of cancer. Frozen serum samples collected from a few months to 19 years prior to clinical recognition of their disease are
available for research purposes. The principle aim of the JANUS project is to search in the premorbid sera for chemical, biochemical, immunological
or other changes that might be indicative of cancer development at early stages. Gas chromatography-mass spectrometry and two-dimensional pro-
tein electrophoresis have been used to evaluate the stability of the frozen sera. Some recent findings are: CA-125 may be elevated months prior to
the diagnosis of ovarian cancer; serum thyroglobulin may be a preclinical tumor marker in subgroups of thyroid cancer; low levels of selenium in
serum reflects increased risk of thyroid cancer; raised antibodies in serum against Epstein-Barr virus is a risk factor for development of Hodgkins
disease; prostate-specific antigen may be elevated years prior to clinical diagnosis of prostate cancer; and linoleic acid in serum phospholipids is
inversely related to breast cancer risk. The serum bank is, in principle, suitable for environmental studies, e.g., human exposure assessment. The
steering committee of the JANUS project is open to suggestions for collaborative research on this topic. - Environ Health Perspect 103 (Suppl
3):85-88(1995)
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Introduction
The JANUS project was started in 1973
(1). It was named after the mythological
god with two faces, symbolizing possibili-
ties for joint prospective and retrospective
studies in sera from cancer patients (1-3).
The serum collection has been an ongoing
task sponsored by the Norwegian Cancer
Society. Serum sampling was terminated
December 31, 1991 but will be started
again in 1995. The status ofthe project up
to 1991 was reported at a meeting in
Vienna 1991 (4). The JANUS serum
bank, as of October 1993, contained
424,938 serum specimens from 293,692
individuals. None ofthem had known can-
cer at the time of blood sampling. Since
1973 and until October 1993, however,
about 14,000 of the blood donors have
developed some type of cancer. Deep-
frozen sera collected from a few months to
19 years prior to diagnosis are thus avail-
able for research. The primary aim of the
This paper was presented at the Conference on
Human Tissue Monitoring and Specimen Banking:
Opportunities for Exposure Assessment, Risk
Assessment, and Epidemiologic Research held
30 March - 1 April 1993 in Research Triangle Park,
North Carolina.
Address correspondence to Dr. Egil Jellum,
Institute of Clinical Biochemistry, Rikshospitalet, 0027
Oslo 1, Norway. Telephone 47 22 867035. Fax 47 22
867029.
JANUS project is to search in these pre-
morbid sera for chemical, biochemical,
immunological, or other changes that
might indicate cancer development at early
stages, or be indicative of increased risk of
cancer (3,4).
The serum bank, however, may also be
of considerable research potential in other
contexts, e.g., in studies of diseases other




The donors ofblood to the collection come
from the Red Cross Blood Center, Oslo;
from the so-called Oslo-investigation on
cardiovascular disease; and from several
counties in Norway, including Finnmark
in northern Norway, Sogn and Fjordane in
western Norway, and Oppland in mid-
Norway (Table 1). In the case of donors
from the Red Cross Blood Center, the rou-
tine was first to collect 450 ml ofblood in
the usual manner. Following this blood
sampling, 50 ml ofblood was collected and
centrifuged. About 20 ml of serum was
aliquoted into 5-ml polyethylene vials and
frozen locally before transportation to the
main storage room where the temperature
was -25°C. The number of Red Cross
blood donors in the JANUS project was
28,664. From 4000 to 6000 blood samples
have been collected from this group of
individuals per year. Samples from young
blood donors (25-30 years of age) were
collected and stored at 3- to 5-year inter-
vals, whereas in the case of the older
donors (>40 years) samples were taken
more frequently, usually at 1- to 2-year
intervals. Thus, for certain individuals the
serum bank may contain up to 13 consecu-
tive blood samples collected since 1973,
whereas in other cases from one to three
samples are available. On average, the Red
Cross Blood donors have contributed
about three samples to the serum bank.
The age distribution of the donors
shows that the Red Cross donors now are
from 24 to 86 years of age, whereas the
Table 1. Number of serum donors and samples in the
JANUS serum bank.
Number of Number of
Collection site donors specimens
Finnmark County 18,000 29,864
Oslo-investigation (men only) 17,647 17,647
Sogn og Fjordane County 19,000 33,595
Oppland County 33,000 88,808
Other counties in Norway 176,881 176,881
Radium-hospital (Oslo) 500 500
Red Cross blood donors 28,664 77,643
Total collection 293,692 424,938
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majority of all the other donors are 52 to
72 years ofage.
Samples contributed from the various
counties in Norway have been drawn from
persons undergoing routine health exami-
nations, particularly in connection with
evaluation ofrisk factors for cardiovascular
disease (5). A considerably smaller volume
ofserum (1-10 ml) is available from these
groups ofdonors, and one to a maximum
of three consecutive samples have been
collected.
Sera from the Red Cross Blood Center
(drawn in conjunction with ordinary blood
donations) have been handled and
aliquoted specifically for the JANUS col-
lection. The lag time between blood sam-
pling and freezing was kept as short as
possible. The quality ofthe Red Cross sera
is therefore better than the left-over sera
obtained (after lipid analysis) from the
other groups ofdonors. In the latter cases
the lag time before freezing was longer and
these sera may have been kept at 4°C for a
day or two before freezing.
It is also important to know that the
collection ofsamples was divided in two
phases. During the first phase, 1973 to
1987, blood was obtained at intervals from
approximately 102,000 donors. After 1987
and up to the end of 1991, sera from an
additional 191,000 persons were included,
making up the total of293,000 donors.
Cancer Follow-up
Since 1951 all new cancer cases in Norway
have been registered by the Cancer
Registry of Norway. This compilation is
based on compulsory reporting by hospital
departments and histopathologic laborato-
ries, and covers the total population (4.5
million inhabitants) of Norway. In 1960
all inhabitants ofthis country were given
individual identification numbers (11 dig-
its), and since that time all newborns and
immigrants to Norway are systematically
given such numbers. All blood donors to
the JANUS collection consequently have
identification numbers and these are regu-
larly (e.g., once ayear) linked with the data
file ofthe Cancer Registry. The following
numbers illustrate the cumulative cancer
cases in the Janus material, based on the
initial 102,000 donors: 1976, 250 cases;
1983, 1800 cases; 1986, 2700 cases; 1990,
4300 cases; autumn 1991, 5000 cases; and
spring 1993, about 6000 cases. In addition
there are about 8000 cumulative cancer
cases among the 192,000 donors added to
the collection since 1987. Thus the total
cumulative number ofcancers among the
293,000 donors is about 14,000 cases,
expected to rise to almost 40,000 cases by
the year 2000. The rapidly increasing
number of cancer cases obviously reflects
the increased risk ofcancer with advancing
age of the donors. The dominant malig-
nancies are skin, breast, lung, and colon
cancer.
Further information on each case,
including date ofcancer diagnosis, type of
cancer, histopathologic diagnosis, and stage
and localization ofthe disease can readily
be obtained from the Cancer Registry.
Sample Retrieval
The serum samples are stored inside a
large, commercially operated cold storage
plant. The temperature is -25°C. The sam-
ples are placed in square boxes (cartons)
containing 100 samples. These cartons are
contained in large cardboard boxes which
again are placed on removable benches.
These benches may be selected by means of
the plant's data system and retrieved by
trucks. Each vial is labeled with date of
blood sampling and identification number.
The box number and the position ofeach
sample in the small box with 100 samples
have been catalogued and can easily be
retrieved by our own data system. The
samples to be analyzed are manually picked
out, thawed and aliquoted before refreez-
ing. In general two to three age-, sex- and
storage-matched control specimens (i.e.,
from JANUS donors who have not yet
developed cancer) are retrieved for every
patient sample. All samples are given a new
and internal code before shipment at
-70°C (surrounded by solid carbon diox-
ide) to the collaborating laboratories.
Because the analyses are "blind" and
because the code is not broken until after
completion ofthe analyses, bias is avoided.
Moreover, the coding ensures a high degree
ofconfidentiality, and patient names and
birthday numbers are not disclosed.
Stability ofthe Frozen
Serum Specimens
This important question has been
approached in several ways. High resolu-
tion two-dimensional (2D) protein elec-
trophoresis has been carried out on series
of serum specimens from the same blood
donors, with up to 10 years difference in
storage time between early and late sam-
ples. The 2D-protein patterns were surpris-
ingly constant over the years, with only
minor changes (6,7). A similar condusion
has been reached by Tracy et al. (8). It
should be emphasized, however, that the
2D-analyses were carried out in the pres-
ence ofreducing and denaturating agents
(mercaptoethanol and 8 M urea). The
above results therefore indicate that the
primary structure of the proteins with-
stands storage at -25°C quite well, but do
not allow conclusions concerning the sta-
bility of the tertiary structure and biologi-
cal activities of the serum proteins.
Undoubtedly, the activity of certain
enzymes will gradually be lost, whereas
other enzymes are reasonably stable for
manyyears.
With regard to immunologic activities
(e.g., antibodies and antigens), the situa-
tion is more favorable than in the case of
enzymes, as the immunologic properties
often may be related to the primary protein
structure. The HIV antibody, for example,
appears to be stable for several years under
our storage conditions. Thus, two donors
belonging to the AIDS risk group had
donated blood for several years and their
serum samples were stored as usual.
Retrospective antibody testing could trace
positive results back to 1981, comparable
with the results obtained in 1985. After
1985, HIV antibody testing of blood
donors has become routine in Norway and
no further HIV positive donors have been
found in the JANUS collection. Also anti-
gens, at least some ofthem, appear to be
stable. Thus the CA-125 antigen found in
serum from patients with ovarian cancer
(9) and detected by the OC-125 mono-
clonal antibody appear to withstand
storage at -25°C.
Many metabolites of low molecular
weight, e.g., several organic acids, amino
acids, and carbohydrates are reasonably sta-
ble in serum at -25°C. This has been
demonstrated by using sensitive capillary
gas-chromatography mass-spectrometry
methods in our laboratory. Trace metals in
serum are stable almost indefinitely, and
many inorganic salts are also very stable.
Lipoproteins, certain vitamins (e.g., C and
E), certain oligosaccharides as well as easily
oxidizable serum constituents are likely to
be less stable. Polyunsaturated fatty acids,
with up to six double bonds of both the
omega-3 and omega-6 type, have been
found (using capillary gas chromatography)
to be surprisingly stable under our storage
conditions.
Although our storage condition at
-25°C is not ideal (liquid nitrogen temper-
ature of-190°C, or ultra freezer at -80°C
would obviously be better), one should
keep in mind that even if certain serum
constituents are degraded slowly at -25°C,
in some cases a thorough use of matched
controls can partly compensate for this
change.




During the early years of the JANUS pro-
ject, two principally different analytical
approaches were taken. Multicomponent
analyses, particularly using high resolution
two-dimensional electrophoresis, were used
to monitor changes in the pattern ofseveral
hundred serum proteins (polypeptides).
Single component analyses were aimed at
the determination of specific antigens,
enzymes, isoenzymes, hormones, vira, or
other "markers" assumed to be associated
with cancer. Because the policy of the
JANUS committee has been to make the
serum bank available for collaborative
research, several projects have been initi-
ated both in Norway and other countries.
Some of these projects were discontinued
after some time because ofnegative results.
These include, without going into any
detail, analyses in the premorbid sera of
compounds such as ectopic hormones
(ACTH, HCG, and calcitonin) anti-T and
anti-I titer (a special assay developed by
Abbott Laboratories, Chicago), galactosyl-
transferase isoenzyme II, and certain lung
and breast cancer antigens.
Direct detection of alterations in the
serum protein pattern by means of 2D-
electrophoresis has also been abandoned,
due to the difficulty in detecting trace pro-
teins in the presence ofmajor serum pro-
teins such as albumin, immunoglobulins,
etc. (6).
Other projects have given results that
have been published recently. Briefly these
include the following:
Lung Cancer Antigen. An immune
antitumor factor in lung cancer, isolated by
a group at the Norwegian Radium
Hospital, but not characterized, gave posi-
tive test results several months prior to the
clinical recognition of lung cancer (9).
This was the first study in which the
JANUS bank was used.
Ovarian CancerAntigen - C4 125.
To investigate the sensitivity ofthe CA 125
immunoradiometric assay for occult ovar-
ian neoplasia, serum CA 125 levels were
determined retrospectively in double-blind
fashion for specimens collected from 105
women who subsequently developed ovar-
ian neoplasia, and from 323 matched con-
trols. The distribution of CA 125 levels
was very different between the case and
control populations (p= 0.0001) over the
entire collection-to-diagnosis interval
(range 1-143 months). Median CA 125
levels for all cases, and for those collected
more than 24 or 36 months prior to diag-
nosis, were always in excess of 18 U/ml
compared with a median of 10.9 U/ml for
controls. Halfofthe cases collected within
18 months prior to a diagnosis had CA 125
levels greater than 30 U/ml and one third
had levels greater than 65 U/ml. About one
fourth of those collected prior to 60
months before diagnosis had levels above
30 U/ml. In contrast, approximately 7%
and 0.9% ofcontrols had levels in excess of
30 or 65 U/ml, respectively. Elevations
occurred in cases eventually diagnosed with
localized or advanced cancer, borderline or
frankly malignant disease, but rarely in
cases with mucinous neoplasms.
These results provide an insight into
the preclinical biology ofovarian neoplasia
that may help in designing methods for
early detection or prevention of this dis-
ease, and demonstrate the usefulness ofthe
JANUS serum bank as a resource in evalu-
ating serum tests (10).
Selenium, and Copper, and Thyroid
Cancer. Sera from 43 persons who devel-
oped thyroid cancer on an average 4.8 years
after blood sampling were compared with
sera from 129 controls, matched for sex,
age, place of residence, and year of blood
sampling, with regard to S-Se and S-Cu.
Cases were significantly lower in S-Se than
controls, and the relative risk of thyroid
cancer increased from 1 for levels >1.60
pmole/l, to 7.2 for levels 1.20-1.59
pmole/l to 15.8 for levels <1.20 pmole/l.
Regression analysis showed that the S-Se
concentration decreases the closer a case
comes to the time ofdiagnosis. The relative
risk estimates changed negligibly, however,
when adjusted for this confounder. It is
uncertain whether this adjustment leads to
an erroneous conclusion about the cancer-
protective effect of Se, since estimates of
relative risk in the early, prediagnostic
phase ofthyroid cancer give no solid indi-
cations of a primary preventive effect of
selenium on thyroid cancer. There was no
difference between cases and controls with
regard to S-Cu (11).
Hodgkin's Disease andEpstein-Barr
Virus (EBV). This was a joint study
between several universities and hospitals
in the United States and several serum
banks (12). The findings ofthis joint study
indicate that elevated EBV antibodies are
risk factors for the development of
Hodgkin's disease. The results suggest that
chronic EBV reactivation occurs several
years preceding diagnosis (12).
Serum Thyroglobuline and Thyroid
Cancer. Serum samples taken several years
prior to diagnosis of cancer were analyzed
for thyroglobulin (TG) and thyroid stimu-
lating hormone (TSH). It was found that
80% of those persons having greatly ele-
vated serum thyroglobuline belonged to
the group (43 blood donors) that later
developed thyroid cancer. Calculations
showed that the relative risk ofthyroid can-
cer increases with increasing levels ofTG in
serum. There were no statistical differences
in TSH between the cases and the controls
(13).
Polyunsaturated Fatty Acids in
Serum Phospolipids andRisk ofBreast
Cancer. Sera were analyzed from 87
women who developed breast cancer
(cases) subsequent to blood donation and
sera from 235 women who were free ofany
diagnosed cancer (controls), but were of
similar age and had similar storage time as
the cases. HPLC was used to isolate the
phospholipid fraction, which was trans-
methylated before determination of the
fatty acid profile by capillary GC (14). The
results showed that there was an inverse
relation between linoleic acid (C18:2, n-6)
and risk ofbreast cancer, but this associa-
tion was restricted to women who were 55
years and younger. No similar "protective"
effect was observed with n-3 unsaturated
fatty acids. None of the measured fatty
acids (saturated or unsaturated) showed a
positive association with breast cancer risk
(14).
Prostate-specific Antigen (PSA) and
Prostate Cancer. This study comprised
samples from 31 cases and 62 matched
controls. A two-site immunoradiometric
assay (IRMA) was used based on mono-
clonal antibodies against PSA and magneti-
zable polymer particles as the solid phase.
The results show a significant difference in
PSA levels between the case group and the
control group, leading to an increased
probability of later contracting prostate
cancer if the PSA value exceeds 4 mg/!.
The results support the view that elevated
serum PSA identifies patients at high risk,
and that this cancer can be detected by
PSA measurement years before clinical
diagnosis (15).
Discussion
The JANUS serum bank with systematized
serum collection between 1973 and 1992,
has grown to become one of the largest
banks of sera currently known (16,17).
The collection is available for collaborative
research with early detection of cancer as
the main goal. With the rapidly increasing
number of cancer cases among the (aging)
donors to theJANUS project, the scientific
value of the serum bank will also increase
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in the years ahead. The JANUS idea (1)
was initiated as a retrospective/prospective
cancer study. The combination ofthe large
serum bank with the detailed information
obtainable from the Norwegian Cancer
Registry makes the JANUS project espe-
cially suited for such studies. Although
clinical and histopathologic data on the
cancer cases are easily retrievable, there are
unfortunately only limited data available
on all those donors who have not devel-
oped cancer that serve as controls. In the
future we hope to include medical records
and mortality data on all donors in the
JANUS serum bank.
Although the JANUS project so far has
been devoted to cancer research, the serum
bank is in principle useful for other pur-
poses. Among the 293,000 persons who
have donated blood to the serum bank,
many have contracted diseases other than
cancer, e.g., heart disease, rheumatic dis-
ease, etc. Samples are available from all
these persons, although the retrieval ofthe
specimens will be more difficult because of
lack ofsuitable registries.
One should also consider that the large
serum bank might be used in environmen-
tal studies, e.g., in the area ofhuman expo-
sure assessment. Valuable information
might be obtained by analyzing sequential
samples taken between 1973 and
December 1991, searching for chemical
substances in the sera that might reflect
differences in exposure to environmental
pollutants in this 19-year period. Until
now, however, our serum bank has not
been used for such purposes, but the steer-
ing committee ofthe JANUS bank is open
to suggestions.
Conclusion
A large serum bank containing close to
500,000 serum samples collected from
293,000 persons over a 19-year period is
available for research purposes. So far the
bank has been used on cancer-related
problems, but the serum collection has an
obvious potential also environmental
studies.
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